Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 7Phase EARLY_PHASE1 3Phase 3 1Phase 1/2 1

Status

Withdrawn 3Completed 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Other neoplasm 1Lymphoid 1Breast 1

Conditions

Melanoma 1Lymphoma, T-Cell, Cutaneous 1Breast Cancer Female 1

Interventions

Magnetic Resonance Spectroscopy 5pembrolizumab 4Biopsy 4durvalumab 3atezolizumab 3Radiotherapy 3Radiosurgery 3Cyclophosphamide 3Bevacizumab 3palbociclib 2niraparib 2abemaciclib 2Trastuzumab 2Temozolomide 2Taxes 2Surgical Procedures, Operative 2Specimen Handling 2Melphalan 2Letrozole 2Ketamine 2Irinotecan 2Hydrocortisone 2Gemcitabine 2Ferrosoferric Oxide 2Dexamethasone 2Curcumin 2Blood Specimen Collection 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × durvalumab × Clear all
NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Yale University

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

NCT04088032 2020-07-16

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Stony Brook University

Phase EARLY_PHASE1 Withdrawn
BreastOther neoplasm

Breast Cancer Female

NCT03235869 2018-03-15

Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Withdrawn
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡